
Aribio announced that its oral candidate drug for Alzheimer's disease, 'AR1001' (generic name: mirodenafil), achieved the primary endpoint in the monotherapy group in its global Phase 3 clinical trial (POLARIS-AD). It is assessed as highly significant that approximately 15 years of determination to develop a domestic treatment for dementia has translated into tangible research results. Dementia treatments are considered a field with high development difficulty, where even global big pharma companies have repeatedly failed in clinical trials.
The bio industry first analyzed that the design structure of Aribio's Phase 3 trial for AR1001 was effective. Through consultations with global regulatory authorities, Aribio pre-designated two primary analysis populations (the overall treatment group and the monotherapy group) and evaluated them separately, agreeing that achieving a statistically significant difference compared to placebo in either population would be recognized as meeting the primary efficacy endpoint. This is why Aribio described its global Phase 3 trial for AR1001 as a 'success' despite failing to secure statistical significance in the overall treatment group.
It was also reported that the scene at the 'International Conference on Alzheimer's Disease Clinical Trials' (CTAD 2026) in Boston, USA, where Aribio announced the Phase 3 results for AR1001 in the early hours of the 17th, received enormous attention.
Based on the global Phase 3 results for AR1001, Aribio plans to swiftly proceed with a New Drug Application (NDA) to the US FDA (Food and Drug Administration). If AR1001 succeeds in obtaining approval, it will become the world's first 'oral dementia drug.' Currently, the global dementia treatment market is centered on injectables such as 'Leqembi' and 'Kisunla.' The superior dosing convenience of AR1001 can be recognized in the market as a differentiated competitive advantage.
The key issue is how global regulatory authorities, including the US FDA, will interpret the Phase 3 data for AR1001. While the primary endpoint was met in the monotherapy group, statistical significance was not secured in the overall treatment group. The results of the long-term open-label extension (OLE) study to be conducted separately after the 52nd-week trial period with AR1001 participants may also influence the future approval review process.
Although Aribio laid the foundation for the birth of a domestic oral dementia drug, the lack of active support from the domestic capital market is a regrettable point. After introducing a drug from the erectile dysfunction treatment class from SK Chemicals in 2011, Aribio developed it as an Alzheimer's disease treatment. During approximately 15 years of research, the company attempted to list on the KOSDAQ market multiple times but failed the technical evaluation three times. Ultimately, it failed to enter the stock market and faced difficulties in fundraising. Shareholders also endured hardships for a long period.
In the process of completing the global Phase 3 trial for AR1001, Aribio chose the path of cooperating with Chinese companies to secure funding. In May last year, it signed a global licensing agreement for AR1001 with Fosun Pharma of China. The total contract size was $4.7 billion (approximately 7 trillion won at the exchange rate at the time), setting the highest record among domestic Alzheimer's treatment licensing contracts. Following this, in July last year, Aribio also concluded a strategic equity investment agreement with Fosun Pharma. Fosun Pharma is expected to secure approximately 5% of Aribio's shares and become the third-largest shareholder. Previously, Aribio received approximately 90 billion won as an upfront payment under the licensing agreement from Fosun Pharma. This was used for the final tasks of AR1001's global Phase 3 trial and data analysis.
The global Phase 3 results for Aribio's AR1001 are also significant for K-bio. This is because a domestic company has secured the foundation to independently conduct a global Phase 3 trial and challenge for the world's first approval of an oral dementia drug. It can serve as an important milestone even for the domestic bio industry, which is assessed as lacking experience in the field of global approval trials.
An Aribio official said, "Now is the time to focus on the global approval of AR1001," adding, "Having faced many difficulties, including fundraising, while conducting research on AR1001 for a long period, we feel even more deeply moved by the success of the global Phase 3 trial."